iShares MSCI Emerging Markets ETF (EEM)
- Previous Close
42.97 - Open
43.19 - Bid 43.04 x 34100
- Ask 43.05 x 1300
- Day's Range
42.94 - 43.22 - 52 Week Range
36.38 - 44.64 - Volume
10,421,720 - Avg. Volume
24,910,341 - Net Assets 17.69B
- NAV 42.84
- PE Ratio (TTM) 12.09
- Yield 2.39%
- YTD Daily Total Return 7.25%
- Beta (5Y Monthly) 0.97
- Expense Ratio (net) 0.70%
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is designed to measure equity market performance in the global emerging markets. The underlying index includes large- and mid-capitalization companies and may change over time.
iShares
Fund Family
Diversified Emerging Mkts
Fund Category
17.69B
Net Assets
2003-04-07
Inception Date
Performance Overview: EEM
View MoreTrailing returns as of 9/13/2024. Category is Diversified Emerging Mkts.
People Also Watch
Holdings: EEM
View MoreTop 10 Holdings (25.24% of Total Assets)
Sector Weightings
Recent News: EEM
View More
Research Reports: EEM
View MoreBUY on regulatory advancements and higher guidance
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in multiple sclerosis drugs and launched the first approved treatments for spinal muscular atrophy and Alzheimer's disease. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts, employs 7,570 people, and is a component of the S&P 500.
RatingPrice TargetU.S. stock indices are mostly in the red today, with investors perhaps
U.S. stock indices are mostly in the red today, with investors perhaps experiencing a little 'green exhaustion' after the solid gains booked of late. Also of note, the meaningful news starts to hit the tape tomorrow with the release of the Fed minutes, so getting a little defensive in case the minutes include unwanted news is also defensible.
Biogen Earnings: Shares Undervalued as Cost Controls Materialize and New Launches Accelerate
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
RatingPrice TargetMorningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, online commerce set for acceleration, consolidation; the market may be missing changes afoot at Veolia; an overview of the moat ratings for big biotech firms; and Kraft Heinz, Tyson Foods, and Nutrien.